Table 6.
Incremental Health and Cost for an Increased Use of SITT (Single-Inhaler Triple Therapies)
| SITT Use Increment | % of Adherent Patients | Results: Potential Scenario vs Current Scenario | |||||
|---|---|---|---|---|---|---|---|
| Exacerb. | Deaths | LYs | QALYs | Exacerbation Costs | Total Direct Costs | ||
| Increment 20% SITT | 52.00% | –6835 | –532 | 775 | 594 | –€4,378,201 | –€7,082,105 |
| Increment 40% SITT | 54.98% | –13,669 | –1064 | 1550 | 1189 | –€8,756,217 | –€14,327,774 |
| Increment 60% SITT | 57.94% | –20,504 | –1595 | 2325 | 1783 | –€13,134,232 | –€21,736,991 |
| Increment 80% SITT | 60.94% | –27,338 | –2127 | 3100 | 2377 | –€17,512,248 | –€29,309,757 |
| Increment 100% SITT | 63.12% | –32,323 | –2515 | 3665 | 2811 | –€20,705,555 | –€37,028,592 |
Abbreviations: SITT, single-inhaler triple therapies; LY, life years; QALY, quality-adjusted life years.